Synthesis and Characterization of Diorganotin(IV) Complexes of N(2-Pyridylmethylene)-arylamines and Mutagenicity Testing in vivo of Et2SnCl2·[L 4=N-(2-Pyridylmethylene)-4-tolu-idine]

Applied Organometallic Chemistry

Volumn 12, Issue 7, 1998, Pages 503-513

  Basu Baul, Swarnali ^a,c,d   Basu Baul, Tushar S ^a,c,d   Rivarola, Eleonora ^b   Dakternieks, Dainis ^c   Tiekink, Edward R T ^d   Syng Ai, Christine ^a   Chatterjee, Anupam ^a  

^a NORTH EASTERN HILL UNIVERSITY   (India)

^b UNIVERSITY OF PALERMO   (Italy)

^c DEAKIN UNIVERSITY   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Bone marrow cells; Cell cycle delay; IR; M ssbauer; Mutagenicity; N (2 pyridylmethylene) arylamines; NMR; Organotin; Sister chromatid exchange

Indexed keywords

EID: 0001546026     PISSN: 02682605     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1099-0739(199807)12:7<503::aid-aoc746>3.0.co;2-p     Document Type: Article

References (53)

1. A. J. Crowe and P. J. Smith, J. Organometal. Chem. 224, 223 (1982).
2. A. J. Crowe, P. J. Smith and G. Atassi, Inorg. Chim. Acta 93, 179 (1984).
3. A. J. Crowe, P. J. Smith, C. J. Cardin, H. E. Perge and F. E. Smith, Cancer Lett. 24, 45 (1984).
4. Q. Li, P. Yang, H. Wang and M. Guo, J. Inorg. Biochem. 64, 181 (1996).
5. T. S. Basu Baul and A. Lycka, Polyhedron 11, 2423 (1992).
6. T. S. Basu Baul, D. Dey and D. D. Mishra, Synth. React. Inorg. Met.-Org. Chem. 23, 53 (1993).
7. Anon., Guidelines for the Testing of Chemicals for Mutagenicity, Report on Health and Social Subjects, No. 35, Department of Health, HMSO, London, 1989.
8. B. H. Gray, M. Porvaznik and L. H. Lee, J. Appl. Toxicol. 6, 263 (1986).
9. J. Otera, S. Loka and H. Nozaki, J. Org. Chem. 54, 4013 (1989).
10. K. R. Siebenlist and F. Taketa, Toxicol. Appl. Pharmacol. 58, 67 (1981).
11. L. D. Deleve and N. Kaplowitz, Pharmacol. Ther. 52, 287 (1991).
12. A. Chatterjee and M. Jacob-Raman, Mutat. Res. 175, 73 (1986).
13. J. P. Shaw and I. N. Chou, J. Cell Physol. 129, 193 (1986).
14. A. Chatterjee, M. Jacob-Raman and B. Mohapatra, Mutat. Res. 214, 207 (1989).
15. A. Chattopadhyay, S. Choudhury and A. Chatterjee, Mutagenesis 12, 221 (1997).
16. L. Pendyala, R. Perez, A. Weinstein, J. Zdanowicz and P. J. Creaven, Cancer Chemother. Pharmacol. 40, 38 (1997).
17. T. S. Basu Baul and E. R. T. Tiekink, unpublished results.
18. K. Goto, T. Akematsu, H. Shimagu and T. Suigiyama, Chromosoma 53, 223 (1975).
19. T. K. Chattopadhyay, A. K. Kumar, A. Roy, A. S. Batsanov, E. B. Shamuratov and Y. T. Struchkov, J. Organometal. Chem. 419, 227 (1991).
20. S. Teoh, S. Teo, L. Lee, Y. Chong and E. R. T. Tiekink, Polyhedron 14, 2275 (1995).
21. D. Pitea, G. Favini and D. Grasso, Gazz. Chim. Ital. 100, 301 (1970).
22. Th. Bluhm, unpublished results.
23. M. Wiebcke, Diplomarbeit, Dusseldorf, 1980.
24. D. H. Busch and J. C. Bailar, Jr,J. Am. Chem. Soc. 78, 1137 (1956).
25. W. D. Honnick, M. C. Hughes, C. D. Schaffer and J. J. Zuckerman, Inorg. Chem. 15, 1391 (1976).
26. T. P. Lockhart, J. C. Calabrese and F. Davidson, Organometallics 6, 2479 (1987).
27. K. Kawakami and R. Okawara, J. Organometal. Chem. 6, 249 (1966).
28. N. W. G. Debye and J. J. Zuckerman, Dev. Appl. Spectrosc. 8, 267 (1970).
29. M. Gielen, E. Joosen, T. Mancilla, K. Jurkchat, R. Willem, J. Bernheim, G. Atassi, F. Huber, E. Hoffman, H. Preut and B. Mahvier, Main Group Met. Chem. 10, 147 (1987).
30. S. L. Chadha, P. G. Harrison and K. C. Molloy, J. Organometal. Chem. 202, 247 (1980).
31. S. A. Latt, R. R. Schreck, K. S. Loveday, C. P. Dougherty and C. F. Shwer, in: Advances in Human Genetics, Harris, H. and Hirschhorn, K. (eds), Vol. 10, pp. 267-331, Plenum, New York 1980.
32. L. R. Ferguson, Mutagenic properties of anticancer drugs In: The Genetics of Cancer Ponder, B. A. J. and Waring, M. J. (eds), pp. 177-216, Kluwer Lancaster, USA, 1995.
33. S. M. Sieber and R. H. Adamson, Adv. Cancer Res. 22, 57 (1975).
34. Y. Arakawa and O. Wada, 2nd Int. Symp. Tin and Malignant Cell Growth, University of Scranton, Scranton, PA 1985, pp. 19-22.
35. Y. Nishi, M. M. Hasegawa, M. Taketomi, Y. Ohkawa and N. Inui, Cancer Res. 44, 3270 (1984).
36. W. D. MacRae, E. A. Mackinnon and H. F. Stich, Chromosoma 72, 15 (1979).
37. P. M. Theodorous, I. Akerboom and S. Helmut, Methods Enzymol. 77, 373 (1981).
38. A. Chatterjee, unpublished results.
39. O. W. Griffith and A. Meister, Proc. Natl. Acad. Sci. U.S.A. 76, 268 (1979).
40. F. Y. F. Lee, M. J. Allunis-Turner and D. W. Siemann, Br. J. Cancer 56, 33 (1987).
41. J. F. Ward, Int. J. Radiat. Biol. 66, 427 (1994).
42. J. Nygren, M. Ljungman and G. Ahnstrom, Int. J. Radiat. Biol. 68, 11 (1995).
43. A. J. Crowe, Drugs of the Future 12, 255 (1987).
44. H. G. Modig, Biochem. Pharmacol. 17, 177 (1968).
45. H. G. Modig, Biochem. Pharmacol. 22, 1623 (1973).
46. P. E. Brown, Nature London 213, 363 (1976).
47. A. Meister, Pharmacol. Ther. 51, 155 (1991).
48. J. M. Barnes and H. B. Stoner, Br. J. Ind. Med. 15, 15 (1958).
49. A. Chatterjee, A. Chattopadhyay and C. J. Z. Lawlor, Mutat. Res. 327, 171 (1995).
50. A. Meister, Science 220, 472 (1983).
51. A. E. Saxena and F. Huber, Coord. Chem. Rev. 95, 109 (1989).
52. L. R. Ferguson and W. A. Denny, Mutat. Res. 331, 1 (1995).
53. P. Brookes, Mutat. Res. 233, 3 (1990).